Bausch Agrees $300m Glumetza Antitrust Settlement As Lupin Awaits Trial

Bausch Health, which rebranded from Valeant Pharmaceuticals following a list of controversies, has reached a proposed settlement deal worth $300m to resolve claims it paid off ANDA sponsor Lupin to delay generic entry for a generic to its Glumetza brand, paving the way for an extraordinary price hike.